1. Home
  2. ELE vs MNKD Comparison

ELE vs MNKD Comparison

Compare ELE & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elemental Royalty Corporation

ELE

Elemental Royalty Corporation

HOLD

Current Price

$15.70

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$4.13

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELE
MNKD
Founded
N/A
1991
Country
Canada
United States
Employees
39
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
ELE
MNKD
Price
$15.70
$4.13
Analyst Decision
Strong Buy
Buy
Analyst Count
1
8
Target Price
$32.50
$8.69
AVG Volume (30 Days)
496.2K
4.7M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
0.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$348,966,000.00
Revenue This Year
$109.25
$35.81
Revenue Next Year
$16.14
$11.89
P/E Ratio
$255.64
N/A
Revenue Growth
N/A
22.23
52 Week Low
$14.01
$2.23
52 Week High
$26.96
$6.51

Technical Indicators

Market Signals
Indicator
ELE
MNKD
Relative Strength Index (RSI) 48.35 54.62
Support Level $14.43 $3.81
Resistance Level $17.83 $4.29
Average True Range (ATR) 0.78 0.22
MACD 0.03 -0.04
Stochastic Oscillator 54.64 56.77

Price Performance

Historical Comparison
ELE
MNKD

About ELE Elemental Royalty Corporation

Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments. It is the result of the strategic merger of Elemental Altus Royalties and EMX Royalty Corporation together creating a mid-tier gold-focused royalty company with the scale, diversification, and cash flow. Geographically, the company generates revenue from North America, South America, Europe, Australia and Africa.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: